Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

NRXP gains DARPA SPARC-TMS contract; potential FDA path for NRX-101

Sep 30, 2026, 8:01 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

DARPA funding, enrollment start, and potential FDA pathway create near-term upside risk/reward; long-run value tied to regulatory success and market adoption.

AI summary

What happened, with direct paths to the underlying reporting

NRXP’s NRXD subsidiary won a DARPA contract worth $11.18 million to run the SPARC-TMS trial, pairing a one-day robotic TMS session with NRX-101. If SPARC-TMS replicates prior 91% response and 69% remission in 3 months, it could become an FDA registration study for NRX-101 with TMS, expanding addressable CNS markets. Partnerships with HOPE Therapeutics, McLean Hospital, ASU, and others could accelerate deployment in military settings.

NRx Defense lands $11.18M DARPA contract for SPARC-TMS trial.
One-day TMS plus NRX-101 shows 91% response, 69% remission in prior data.
If replicated, SPARC-TMS could support FDA registration for NRX-101 with TMS.
Partnerships with HOPE Therapeutics, McLean Hospital, ASU; expanding military site trials.
Trial uses robotic 1mm-precision TMS; no anesthesia required.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

NRXP gains DARPA SPARC-TMS contract; potential FDA path for NRX-101

NRx Pharmaceuticals Set to Report Q1 Earnings with Positive Developments

More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

FDA Submission for Abbreviated New Drug Application; $750 Million Market for Suicidal Depression Market Awaits Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

Three Revenue-Generating Facilities in Florida Plus Six More by Year-End in Expanding $750 Million Market Suicidal Depression Market: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)